Biocryst Pharmaceuticals (BCRX) Interest Expenses (2011 - 2026)

Biocryst Pharmaceuticals has reported Interest Expenses for 16 years, with the latest figure at $19.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 15.81% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $75.2 million (down 22.92% YoY), and the FY2025 full-year result was $78.9 million, down 19.94% from the prior year.
• Interest Expenses for Q1 2026 stood at $19.8 million, up from $14.1 million in the prior quarter.
• The five-year high for Interest Expenses was $28.9 million in Q2 2023, with the low at $14.1 million in Q4 2025.
• Historically, Interest Expenses has averaged $23.8 million across 5 years, with a median of $24.5 million in 2024.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 84.73% — and 2025, when it sank 42.19%.
• Biocryst Pharmaceuticals' Interest Expenses stood at $26.5 million in 2022, then decreased by 7.09% to $24.6 million in 2023, then dropped by 0.55% to $24.4 million in 2024, then slumped by 42.19% to $14.1 million in 2025, then surged by 39.93% to $19.8 million in 2026.
• The last three Interest Expenses figures came in at $19.8 million (Q1 2026), $14.1 million (Q4 2025), and $19.7 million (Q3 2025), per Business Quant data.